Please login to the form below

Not currently logged in
Email:
Password:

Quillivant XR

This page shows the latest Quillivant XR news and features for those working in and with pharma, biotech and healthcare.

Pfizer enters ADHD market with Quillivant XR launch

Pfizer enters ADHD market with Quillivant XR launch

Pfizer enters ADHD market with Quillivant XR launch. Gained rights last November as part of NextWave acquisition. ... The efficacy of Quillivant XR was evaluated in a randomized, double-blind, placebo-controlled, crossover, multicentre, laboratory

Latest news

  • Pfizer concludes NextWave acquisition Pfizer concludes NextWave acquisition

    After closing the deal, Pfizer now holds exclusive North American rights to Quillivant XR (methylphenidate HCl), an extended-release ADHD drug in a child-friendly liquid formulation that can be given ... Quillivant XR was approved by the FDA in September

  • Pfizer pays $680m to buy ADHD drug developer NextWave Pfizer pays $680m to buy ADHD drug developer NextWave

    Pfizer pays $680m to buy ADHD drug developer NextWave. Portfolio includes once-daily Quillivant XR. ... In addition to Quillivant XR, NextWave is developing a chewable tablet formulation of methylphenidate - codenamed NWP09 - that is due to be filed for

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    Established products – new formulations. Pfizer's acquisition of NextWave Pharmaceuticals bolsters its established products business unit bringing Quillivant XR (methylphenidate hydrochloride), which recently secured FDA approval for attention

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics